375 related articles for article (PubMed ID: 31481080)
1. Functional exosome-mediated co-delivery of doxorubicin and hydrophobically modified microRNA 159 for triple-negative breast cancer therapy.
Gong C; Tian J; Wang Z; Gao Y; Wu X; Ding X; Qiang L; Li G; Han Z; Yuan Y; Gao S
J Nanobiotechnology; 2019 Sep; 17(1):93. PubMed ID: 31481080
[TBL] [Abstract][Full Text] [Related]
2. Effect of platelet exosomes loaded with doxorubicin as a targeted therapy on triple-negative breast cancer cells.
Uslu D; Abas BI; Demirbolat GM; Cevik O
Mol Divers; 2024 Apr; 28(2):449-460. PubMed ID: 36576666
[TBL] [Abstract][Full Text] [Related]
3. Targeted exosome-encapsulated erastin induced ferroptosis in triple negative breast cancer cells.
Yu M; Gai C; Li Z; Ding D; Zheng J; Zhang W; Lv S; Li W
Cancer Sci; 2019 Oct; 110(10):3173-3182. PubMed ID: 31464035
[TBL] [Abstract][Full Text] [Related]
4. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer.
Deng X; Cao M; Zhang J; Hu K; Yin Z; Zhou Z; Xiao X; Yang Y; Sheng W; Wu Y; Zeng Y
Biomaterials; 2014 May; 35(14):4333-44. PubMed ID: 24565525
[TBL] [Abstract][Full Text] [Related]
5. Exosome-sheathed porous silica nanoparticle-mediated co-delivery of 3,3'-diindolylmethane and doxorubicin attenuates cancer stem cell-driven EMT in triple negative breast cancer.
Sarkar R; Biswas S; Ghosh R; Samanta P; Pakhira S; Mondal M; Dutta Gupta Y; Bhandary S; Saha P; Bhowmik A; Hajra S
J Nanobiotechnology; 2024 May; 22(1):285. PubMed ID: 38796426
[TBL] [Abstract][Full Text] [Related]
6. Glutamine-β-cyclodextrin for targeted doxorubicin delivery to triple-negative breast cancer tumors via the transporter ASCT2.
Zhou P; Liang X; Zhou C; Qin J; Hou C; Zhu Z; Zhang W; Wang S; Zhong D
J Mater Chem B; 2019 Sep; 7(35):5363-5375. PubMed ID: 31403158
[TBL] [Abstract][Full Text] [Related]
7. Combined mTOR inhibitor rapamycin and doxorubicin-loaded cyclic octapeptide modified liposomes for targeting integrin α3 in triple-negative breast cancer.
Dai W; Yang F; Ma L; Fan Y; He B; He Q; Wang X; Zhang H; Zhang Q
Biomaterials; 2014 Jul; 35(20):5347-5358. PubMed ID: 24726747
[TBL] [Abstract][Full Text] [Related]
8. Exosomes decrease sensitivity of breast cancer cells to adriamycin by delivering microRNAs.
Mao L; Li J; Chen WX; Cai YQ; Yu DD; Zhong SL; Zhao JH; Zhou JW; Tang JH
Tumour Biol; 2016 Apr; 37(4):5247-56. PubMed ID: 26555545
[TBL] [Abstract][Full Text] [Related]
9. Engineering macrophage-derived exosomes for targeted chemotherapy of triple-negative breast cancer.
Li S; Wu Y; Ding F; Yang J; Li J; Gao X; Zhang C; Feng J
Nanoscale; 2020 May; 12(19):10854-10862. PubMed ID: 32396590
[TBL] [Abstract][Full Text] [Related]
10. Stat3/Oct-4/c-Myc signal circuit for regulating stemness-mediated doxorubicin resistance of triple-negative breast cancer cells and inhibitory effects of WP1066.
Cheng CC; Shi LH; Wang XJ; Wang SX; Wan XQ; Liu SR; Wang YF; Lu Z; Wang LH; Ding Y
Int J Oncol; 2018 Jul; 53(1):339-348. PubMed ID: 29750424
[TBL] [Abstract][Full Text] [Related]
11. Engineering blood exosomes for tumor-targeting efficient gene/chemo combination therapy.
Zhan Q; Yi K; Qi H; Li S; Li X; Wang Q; Wang Y; Liu C; Qiu M; Yuan X; Zhao J; Hou X; Kang C
Theranostics; 2020; 10(17):7889-7905. PubMed ID: 32685027
[No Abstract] [Full Text] [Related]
12. Dual-targeted hybrid nanoparticles of synergistic drugs for treating lung metastases of triple negative breast cancer in mice.
Zhang T; Prasad P; Cai P; He C; Shan D; Rauth AM; Wu XY
Acta Pharmacol Sin; 2017 Jun; 38(6):835-847. PubMed ID: 28216624
[TBL] [Abstract][Full Text] [Related]
13. A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy.
Tian Y; Li S; Song J; Ji T; Zhu M; Anderson GJ; Wei J; Nie G
Biomaterials; 2014 Feb; 35(7):2383-90. PubMed ID: 24345736
[TBL] [Abstract][Full Text] [Related]
14. A33 antibody-functionalized exosomes for targeted delivery of doxorubicin against colorectal cancer.
Li Y; Gao Y; Gong C; Wang Z; Xia Q; Gu F; Hu C; Zhang L; Guo H; Gao S
Nanomedicine; 2018 Oct; 14(7):1973-1985. PubMed ID: 29935333
[TBL] [Abstract][Full Text] [Related]
15. Bioinspired exosome-mimetic nanovesicles for targeted delivery of chemotherapeutics to malignant tumors.
Jang SC; Kim OY; Yoon CM; Choi DS; Roh TY; Park J; Nilsson J; Lötvall J; Kim YK; Gho YS
ACS Nano; 2013 Sep; 7(9):7698-710. PubMed ID: 24004438
[TBL] [Abstract][Full Text] [Related]
16. Doxorubicin-polyglycerol-nanodiamond conjugate is a cytostatic agent that evades chemoresistance and reverses cancer-induced immunosuppression in triple-negative breast cancer.
Yuan SJ; Xu YH; Wang C; An HC; Xu HZ; Li K; Komatsu N; Zhao L; Chen X
J Nanobiotechnology; 2019 Oct; 17(1):110. PubMed ID: 31623629
[TBL] [Abstract][Full Text] [Related]
17. The application of aptamer 5TR1 in triple negative breast cancer target therapy.
Luo S; Wang S; Luo N; Chen F; Hu C; Zhang K
J Cell Biochem; 2018 Jan; 119(1):896-908. PubMed ID: 28671278
[TBL] [Abstract][Full Text] [Related]
18. Folate-modified poly(2-ethyl-2-oxazoline) as hydrophilic corona in polymeric micelles for enhanced intracellular doxorubicin delivery.
Qiu LY; Yan L; Zhang L; Jin YM; Zhao QH
Int J Pharm; 2013 Nov; 456(2):315-24. PubMed ID: 24016742
[TBL] [Abstract][Full Text] [Related]
19. Intercellular adhesion molecule 1 antibody-mediated mesoporous drug delivery system for targeted treatment of triple-negative breast cancer.
Wang M; Liu W; Zhang Y; Dang M; Zhang Y; Tao J; Chen K; Peng X; Teng Z
J Colloid Interface Sci; 2019 Mar; 538():630-637. PubMed ID: 30554096
[TBL] [Abstract][Full Text] [Related]
20. Doxorubicin-Loaded Micelle Targeting MUC1: A Potential Therapeutic for MUC1 Triple Negative Breast Cancer Treatment.
Khondee S; Chittasupho C; Tima S; Anuchapreeda S
Curr Drug Deliv; 2018; 15(3):406-416. PubMed ID: 28707580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]